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The Hajj is a unique annual mass gathering that is mandated on
all able Muslims as a central tenet of their faith. As a result of this,
each year over 2 million pilgrims from more than 160 countries
congregate in Mecca. Given the overcrowded conditions that
characterize the pilgrimage, respiratory infections are a leading
cause of morbidity in pilgrims,1–3 and pneumonia accounts for a
third of the reasons for hospitalization into Saudi hospitals during
the Hajj.4,5 In 2004, pneumonia was the commonest source of severe
sepsis and septic shock during the pilgrimage (55%), with
Streptococcus pneumoniae as a leading organism isolated.6 While
inﬂuenza vaccine is recommended to Hajj pilgrims by the Saudi
Ministry of Health, vaccination against invasive pneumococcal
disease (IPD) is not.7 This contrasts with French recommendations,
which advocate its use in pilgrims aged 60 years and over, and in
younger individuals with certain chronic conditions.8
With the aim of assessing vaccination coverage against IPD, we
conducted a prospective study among 632 pilgrims attending two
travel medicine centers in Marseille, France for the required
vaccination against meningitis prior to the 2010 Hajj. The male-to-
female sex ratio was 1.19 and the median age was 62 years (range
19–87 years). Most of the individuals were traveling to Saudi
Arabia for the ﬁrst time (72.5%). Countries of birth were located
mainly in North Africa (90.7%), with 48.7% in Algeria, 25.0% in
Morocco, and 15.0% in Tunisia. The remaining pilgrims were born
in France (6.5%) or elsewhere in Africa and Europe (4.7%). Most
foreign-born pilgrims appeared to have lived in France for at least
20 years (83.1%). Only 11 (1.7%) individuals declared that they
were vaccinated against IPD before consulting, while 198 (31.3%)
had an indication for vaccination according to French guidelines,
independent of their project to perform the Hajj (recommended in
the general adult population with certain chronic conditions only)
and 353 (55.9%) had an indication according to US guidelines,
where vaccination is routinely indicated in individuals aged over
64 years and in those under 64 with certain chronic conditions.9,10
Pilgrims originating from Algeria were signiﬁcantly more likely toTable 1
Vaccination coverage against pneumococcal infections in Hajj pilgrims consulting
before departure, Marseille, France
Age and medical status Number of
individuals
Vaccination against
pneumococcal infection
(less than 5 years ago)
Individuals <65 years,
without chronic diseases
279 3 (1.1%)
Individuals <65 years,
with chronic diseasesa
146 5 (3.4%)
Individuals >65 years,
without chronic diseases
155 2 (1.3%)
Individuals >65 years,
with chronic diseasesa
51 1 (2.0%)
a Diabetes 153 (24.2%), chronic respiratory disease 34 (5.4%), chronic cardiac
disease 30 (4.7%), chronic renal failure 4 (0.6%).
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doi:10.1016/j.ijid.2011.07.001have an indication (68.5%) compared to others (43.8%), by
American guidelines for pneumococcal vaccination (odds ratio
2.79, 95% conﬁdence interval 1.99–3.95). Our results indicate very
low vaccination coverage against IPD in French pilgrims before
departing to Saudi Arabia (Table 1). Given, the risk of IPD during
the Hajj, we propose that the pneumococcal vaccine be offered to
all older pilgrims and to younger pilgrims with chronic conditions.
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